Provider: Wright Reports
Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV And Merck KGaA's Merck Serono Further Strengthen Their Collaboration On Co-discovery And Co-development Of Nanobodies
Ablynx NV and Merck Serono, the biopharmaceutical division of Merck KGaA, announced that they have further expanded their relationship through a multi-year research alliance that could lead to at least four co-discovery and co-development collaborations. Under the terms of the agreement, Merck Serono will fund a dedicated discovery group at Ablynx. Both partners will jointly select disease targets against which this group will develop Nanobodies, up to in vivo proof-of-principle. The dedicated group will focus on the discovery and development of Nanobodies against a number of targets across multiple disease areas. The collaboration will span all of Merck Serono's core research and development fields, including oncology, immuno-oncology, immunology and neurology.
Latest Developments for Ablynx NV
- Ablynx NV on track to start Phase III study in patients with acquired TTP in mid 2015
- Ablynx NV's anti-Il-6r nanobody partnered with Abbvie demonstrates a bioavailability of more than 80 pct after subcutaneous injection
- Ablynx NV's Anti-vwf Nanobody, Caplacizumab, achieves clinical proof-of-concept in Phase II Titan study
- Ablynx to present additional positive data on anti-IL-6R Nanobody ALX-0061
Latest Key Developments in Biotechnology
- Share this
- Digg this